Objectives: This study evaluated the use of an injectable hydrogel derived from ventricular
extracellular matrix (ECM) for treating myocardial infarction (MI) and its ability to be delivered …

New therapies are needed to prevent heart failure after myocardial infarction (MI). As
experimental treatment strategies for MI approach translation, safety and efficacy must be …

A variety of decellularized materials have been developed that have demonstrated potential
for treating cardiovascular diseases and improving our understanding of cardiac …

Background: There is increasing need for better therapies to prevent the development of
heart failure after myocardial infarction (MI). An injectable hydrogel derived from …

This study evaluated the safety and feasibility of transendocardial injections of VentriGel, a
cardiac extracellular matrix hydrogel, in early and late post–myocardial infarction (MI) …

Heart failure (HF) after myocardial infarction (MI) is a leading cause of death in the western
world with a critical need for new therapies. A previously developed injectable hydrogel …

Injectable materials offer the potential for minimally invasive therapy for myocardial infarction
(MI), either as an acellular scaffold or as a cell delivery vehicle. A recently developed …

Intramyocardial hydrogel injection is an innovative and promising treatment for myocardial
infarction (MI) and has recently entered clinical trials. By providing mechanical support to the …

Introduction: Heart failure following myocardial infarction (MI) impacts millions of people
each year in the US. The field of tissue engineering has developed several potential …

Decellularized extracellular matrix in the form of patches and locally injected hydrogels has
long been used as therapies in animal models of disease. Here we report the safety and …